Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Credit Suisse Maintains Outperform on PRA Health Sciences, Raises Price Target to $169

Author: Benzinga Newsdesk | April 29, 2021 10:42am
Credit Suisse analyst Erin Wright maintains PRA Health Sciences (NASDAQ:PRAH) with a Outperform and raises the price target from $159 to $169.

Posted In: PRAH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist